Phase 3 N=229 Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study
Osteoporosis
Primary: Bone Turnover Markers — -4.627; -0.405; -4.297; -6.126 Percent change from baseline
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=44 Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
Renal Failure · Tremors
Primary: Evaluation of Hand Tremor and Stable Kidney Transplant Patients When Switched From Prograf to LCP-Tacro. — 25.30; 19.96; -5.35 units on a scale — p=0.0048
N/A N=39 Do Group Insulin Education Visits Reduce Barriers to Insulin Initiation?
Diabetes Mellitus, Type 2
Primary: Change in "Barriers to Insulin Treatment (BIT)" Score From Before to After the Classes — -0.76; -0.42; 0.88; -0.55 units on a scale
Phase 2 N=16 N-acetylcysteine and NMDA Antagonist Interactions
Cognitive Dysfunction
Primary: Target P300 — 2.5; 3.2; 5.2; 3.4 microvolts
Phase 2 N=55 Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival Rate — 10.3 months — p=0.10
N/A N=501 Lesion Detection of Automated Breast Ultrasound Compared With Handheld Physician-performed Breast Ultrasound
Breast Diseases
Primary: Ratio of Lesions Detected With Automated Breast Ultrasound (ABVS) Compared to the Standard of Care Handheld (HH) Breast Ultrasound (US) — 1.19 Detection ratio of lesions
Phase 2 N=376 Enhancing Prevention Capacity With Developmental Assets and Getting to Outcomes
Substance Abuse
Primary: Prevention Capacity-GTO Efficacy (Intent to Treat) — 63.38; 59.79; 61.37; 58.71 percentage of the highest possible score — p=.58
N/A N=19 Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS)
Hyperglycemia
Primary: Device Performance: Accuracy of HGMS — 12.8 percent difference
Phase 2 N=131 Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Opioid Induced Constipation
Primary: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment — 1.96; 3.42; 1.44 Number of SBMs/week
Phase 2 N=145 Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
Breast Cancer
Primary: Number of Patients With Pathological Complete Response — 34; 17 participants
Phase 2 N=59 Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin
Type 1 Diabetes Mellitus
Primary: Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]) — 31.75; 30.99 percentage of time — p=0.7304
Phase 1 N=25 Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin
Hypercholesterolemia · Dyslipidemia
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615 — 17950000; 933800 nanogram*hour per milliliter
Phase 2 N=50 A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
Chronic Hepatitis C
Primary: Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Triple Therapy Treatment Arms (A, D, and E) — -0.881; -2.321; -2.020 Log10(IU/mL)
N/A N=458 Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
Sepsis · Disease Progression · Septic Shock
Primary: Proportion of the Patients Who Require Vasopressor/Mechanical Ventilator — 53; 21 participants
Phase 2 N=408 Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Change From Baseline in the Average Pain Score (NPRS) for Week 2 — -2.20; -2.24; -1.57; -1.77 units on a scale